• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [17098 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Agency for Care Effectiveness (ACE) Advanced hybrid closed loop system for people with type 1 diabetes mellitus
2025     Agency for Care Effectiveness (ACE) Intraoperative cell salvage for surgeries with anticipated or possible significant blood loss
2025     Agency for Care Effectiveness (ACE) Biomarker-based brain trauma assessment tests to aid in the evaluation of mild traumatic brain injury in adults
2025     Agency for Care Effectiveness (ACE) Portable Neuromodulation Stimulator (PoNS) for treating gait deficit due to multiple sclerosis
2025     Agency for Care Effectiveness (ACE) LumiSystem for intraoperative tumour margin assessment following breast-conserving surgery
2025     Agency for Care Effectiveness (ACE) Edison Histotripsy System for non-invasive destruction of liver tumours
2025     National Institute for Health and Care Excellence (NICE) Slide sheets for moving or repositioning a person: late-stage assessment. NICE HealthTech guidance 745
2025     National Institute for Health and Care Excellence (NICE) Drug-eluting stents for treating coronary artery disease: late-stage assessment. NICE HealthTech guidance 747
2025     National Institute for Health and Care Excellence (NICE) Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment. NICE HealthTech guidance 751
2025     National Institute for Health and Care Excellence (NICE) Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment. NICE HealthTech guidance 753
2025     National Institute for Health and Care Excellence (NICE) One-piece closed bags for colostomies: late-stage assessment. NICE HealthTech guidance 754
2025     National Institute for Health and Care Excellence (NICE) Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment. NICE HealthTech guidance 757
2025     National Institute for Health and Care Excellence (NICE) Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment. NICE HealthTech guidance 759
2025     National Institute for Health and Care Excellence (NICE) Compression products for treating venous leg ulcers: late-stage assessment. NICE HealthTech guidance 758
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment. NICE HealthTech guidance 739
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for orthopaedic procedures: early value assessment. NICE HealthTech guidance 743
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for soft tissue procedures: early value assessment. NICE HealthTech guidance 742
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment. NICE HealthTech guidance 746
2025     National Institute for Health and Care Excellence (NICE) Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment. NICE HealthTech guidance 748
2025     National Institute for Health and Care Excellence (NICE) Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment. NICE HealthTech guidance 756
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment. NICE HealthTech guidance 760
2025     National Institute for Health and Care Excellence (NICE) Digital platforms to support cardiac rehabilitation: early value assessment. NICE HealthTech guidance 761
2025     Scottish Health Technologies Group (SHTG) Esaote® extremity MRI scanners
2025     HTA South [Screening for diabetic retinopathy with artificial intelligence for image analysis: a systematic review and assessment of medical, economical, ethical and organisational aspects]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Guidance for searching and finding public contributions to pharmaceutical R&D
2025     Austrian Institute for Health Technology Assessment (AIHTA) Telecardiology for heart failure patients: Benefit assessment and evaluation concept for telemedicine-supported care programmes in Austria
2025     Austrian Institute for Health Technology Assessment (AIHTA) Nudging interventions to optimise physician prescribing behaviour
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Cervical length screening followed by progesterone with or without additional treatment for short cervix to prevent preterm birth
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Radiofrequency or microwave ablation versus surgery for treatment of benign non-toxic or toxic nodules, and toxic diffuse autoimmune hyperthyroidism (Graves' disease)
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of hospital at home compared with in-hospital care according to current Swedish healthcare routine
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy and safety of parenteral clomipramine compared to oral clomipramine or other treatments for depression or obsessive-compulsive disorder
2025     WorkSafeBC Magnesium to treat chronic pain
2025     WorkSafeBC Arthrosamid® in treating knee osteoarthritis (OA)
2025     WorkSafeBC Efficacy / effectiveness of Ubiquinol® in treating chronic fatigue syndromes post acute COVID-19 syndromes
2025     WorkSafeBC Efficacy/effectiveness of Vyvanse® in treating chronic fatigue syndromes (CFS) or post acute COVID-19 syndromes
2025     WorkSafeBC Efficacy and / or effectiveness of SportVis as treatment for subacromial bursitis - 2025 update
2025     WorkSafeBC Platelet rich plasma in treating disc herniation or facet joint pain
2025     WorkSafeBC Cryotherapy in treating meniscal tears
2025     WorkSafeBC Combining IV and oral ketamine to treat chronic non-cancer pain
2025     WorkSafeBC Complex regional pain syndrome (CRPS) diagnostic criteria at time of evaluation and its role on treatment outcomes
2025     WorkSafeBC Red light therapy for Achilles / other tendon rupture
2025     WorkSafeBC Effectiveness of extra corporeal shockwave therapy (ESWT) in treating biceps tendinopathy
2025     WorkSafeBC Firefighting and coronary heart disease
2025     WorkSafeBC CRPS and dental pain/sensitivity
2025     WorkSafeBC Traumatic brain injury (TBI) without any ocular trauma and cataract development
2025     WorkSafeBC Pulsed electromagnetic field therapy (PEMF), hyperbaric chamber, or acupuncture for treatment of hypersensitivity pneumonitis
2025     WorkSafeBC Meniscal injury and time to TKA: partial meniscectomy vs. conservative treatment
2025     WorkSafeBC Industrial instrument mechanic and development of multiple myeloma
2025     WorkSafeBC The effects of Sb2O3 [antimony trioxide] on human health
2025     WorkSafeBC Tower crane operators and low back pain
2025     WorkSafeBC Firefighting and Crohn’s disease
2025     WorkSafeBC Aerolase® System in treating burn/scar tissue
2025     WorkSafeBC IV ketamine therapy for long Covid
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Maternal and perinatal mortality and severe morbidity of midwife assisted births outside hospital compared with hospital births
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Dental assessment for prevention of medication-related osteonecrosis of the jaw in adults with early breast cancer
2025     Austrian Institute for Health Technology Assessment (AIHTA) Obecabtagene autoleucel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
2025     Austrian Institute for Health Technology Assessment (AIHTA) Social prescribing in primary care. Development of an Austrian programme theory based on realist evidence
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the programme on preventive medical check-ups in Austria. Risk scores for cardiovascular disease: a systematic review
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the programme on preventive health check-ups in Austria. Brief interventions for lifestyle counselling: umbrella review and qualitative survey
2025     National Institute for Health and Care Excellence (NICE) VA ECMO for postcardiotomy cardiogenic shock in adults. NICE interventional procedures guidance 810
2025     National Institute for Health and Care Excellence (NICE) Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1114
2025     National Institute for Health and Care Excellence (NICE) Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 1113
2025     National Institute for Health and Care Excellence (NICE) Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 1115
2025     National Institute for Health and Care Excellence (NICE) Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. NICE technology appraisal guidance 1116
2025     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency. NICE technology appraisal guidance 1117
2025     Austrian Institute for Health Technology Assessment (AIHTA) Enfortumab vedotin in combination with pembrolizumab in urothelial cancer
2025     Austrian Institute for Health Technology Assessment (AIHTA) Transition from child and adolescent to adult mental health services: analysis of international models and recommendations for action for Austria
2025     HTA Region Stockholm [Therapeutic benefits and adverse effects of extended idebenone treatment in Leber hereditary optic neuropathy (LHON)]
2025     NIHR Health Services and Delivery Research programme Integration of specialised services for eating disorders and functional symptom disorders in children and young people: discrete choice experiments and qualitative study
2025     NIHR Health Technology Assessment programme Cost-effectiveness of endoscopic treatments for obesity: a clinical evidence map and systematic review to inform a model-based cost-effectiveness analysis
2025     NIHR Health Technology Assessment programme A community-based rehabilitation package following hip fracture: FEMuR III a multi-centre RCT, economic and process evaluation
2025     NIHR Health Services and Delivery Research programme Witness to harm-holding to account. Improving patient, family and colleague experiences of fitness to practise proceedings: a mixed-methods study
2025     NIHR Health Technology Assessment programme Process evaluation exploring implementation and delivery of a home-based extended exercise intervention for older people with frailty: the HERO trial
2025     Malaysian Health Technology Assessment (MaHTAS) Robotic-assisted surgery for gynaecological disorders
2025     Malaysian Health Technology Assessment (MaHTAS) Apomorphine injection and subcutaneous infusion therapy for advanced Parkinson’s disease
2025     Malaysian Health Technology Assessment (MaHTAS) Microwave ablation for kidney and liver tumours
2025     Malaysian Health Technology Assessment (MaHTAS) 3D-printing for orthosis, prosthesis and exoskeleton
2025     Malaysian Health Technology Assessment (MaHTAS) Laparoscopic indocyanine green sentinel lymph node mapping in endometrial cancer
2025     NIHR Health Services and Delivery Research programme Health visiting in the UK in light of the COVID-19 pandemic experience (RReHOPE): study synopsis
2025     NIHR Health Technology Assessment programme Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviews
2025     NIHR Health Technology Assessment programme Optimal provision of opiate substitution therapy and needle and syringe programmes: a multi-method realist evaluation
2025     NIHR Health Technology Assessment programme Compression Hosiery to Avoid the Post-Thrombotic Syndrome: a synopsis of the CHAPS RCT
2025     NIHR Health Services and Delivery Research programme Proactive integrated consultation-liaison psychiatry for older medical inpatients: The HOME Study RCT of its effectiveness and cost-effectiveness
2025     NIHR Health Technology Assessment programme Accuracy and clinical effectiveness of fetal growth monitoring strategies for the prediction of small for gestational age at birth: a systematic review and meta-analysis
2025     NIHR Health Technology Assessment programme Behavioural weight management interventions for the treatment of obesity: network meta-analysis of trial and real-world individual participant data
2025     NIHR Health Technology Assessment programme Dismantling behavioural weight management interventions: component network meta-analysis of randomised controlled trials and real-world services
2025     NIHR Health Technology Assessment programme Risk assessment tools for predicting transfusion in surgery: a systematic review and meta-analysis
2025     NIHR Health Services and Delivery Research programme Developing palliative and end-of-life care research partnerships in the North East and North Cumbria: a report on the first year of the RIPEN network
2025     The Danish Health Technology Council (DHTC) [Evaluation report concerning supervised walking exercise for patients with intermittent claudication]
2025     National Institute for Health and Care Excellence (NICE) Low-energy contact X-ray brachytherapy for rectal cancer. NICE interventional procedures guidance 809
2025     National Institute for Health and Care Excellence (NICE) Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 1108
2025     National Institute for Health and Care Excellence (NICE) Delgocitinib for treating moderate to severe chronic hand eczema. NICE technology appraisal guidance 1107
2025     National Institute for Health and Care Excellence (NICE) Cabotegravir for preventing HIV-1 in adults and young people. NICE technology appraisal guidance 1106
2025     National Institute for Health and Care Excellence (NICE) Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 1109
2025     National Institute for Health and Care Excellence (NICE) Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal). NICE technology appraisal guidance 1111
2025     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal). NICE technology appraisal guidance 1112
2025     National Institute for Health and Care Excellence (NICE) Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 1110
2025     NIHR Health Technology Assessment programme Brief psychodynamic-interpersonal therapy for adults with a history of self-harm: the SafePIT RCT
2025     Penn Medicine Center for Evidence-based Practice (CEP) Tools for predicting imminent death
2025     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for glycogen storage disease, Type II (GSD II; Pompe disease)